Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer

Human epidermal growth factor receptor 3 (HER3) expression in lung and breast cancers has a negative impact on survival. Patritumab, a human anti‐HER3 mAb, has shown anticancer activity in preclinical models. This study examined the safety and pharmacokinetics of patritumab in combination with trast...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Hirofumi, Saeki, Toshiaki, Aogi, Kenjiro, Naito, Yoichi, Matsubara, Nobuaki, Shigekawa, Takashi, Ueda, Shigeto, Takashima, Seiki, Hara, Fumikata, Yamashita, Tomonari, Ohwada, Shoichi, Sasaki, Yasutsuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084669/
https://www.ncbi.nlm.nih.gov/pubmed/27452985
http://dx.doi.org/10.1111/cas.13017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084669/
https://www.ncbi.nlm.nih.gov/pubmed/27452985
http://dx.doi.org/10.1111/cas.13017

Ejemplares similares